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Between 2003 and 2012, 42 869 first liver transplanta-
tions performed in Europe with the use of either
University of Wisconsin solution (UW; N¼ 24562),
histidine-tryptophan-ketoglutarate(HTK; N¼ 8696),
Celsior solution (CE; N¼ 7756) or Institute Georges
Lopez preservation solution (IGL-1; N¼ 1855) pre-
served grafts. Alternative solutions to the UW were
increasingly used during the last decade. Overall, 3-
year graft survival was higher with UW, IGL-1 and CE
(75%, 75%and73%, respectively), compared to theHTK
(69%) (p< 0.0001). The same trendwasobservedwith a
total ischemia time (TIT) >12h or grafts used for
patients with cancer (p< 0.0001). For partial grafts, 3-
year graft survival was 89% for IGL-1, 67% for UW, 68%
for CE and 64% for HTK (p¼ 0.009). Multivariate
analysis identified HTK as an independent factor of
graft loss, with recipient HIV (þ), donor age 65 years,
recipient HCV (þ), main disease acute hepatic failure,
use of a partial liver graft, recipient age 60 years, no
identical ABO compatibility, recipient hepatitis B
surface antigen (), TIT 12h, male recipient and
main disease other than cirrhosis. HTK appears to be
an independent risk factor of graft loss. Both UW and
IGL-1, andCE to a lesser extent, provides similar results
for full size grafts. For partial deceased donor liver
grafts, IGL-1 tends to offer the best graft outcome.
Abbreviations: CE, Celsior solution; ELTR, European
Liver Transplant Registry; HCC, hepatocellular carcino-
ma; HES, hydroxyethyl starch; HTK, histidine-trypto-
phan-ketoglutarate solution; IGL-1, Institute Georges
Lopez preservation solution; LT, liver transplantation;
PEG, polyethylene glycol; TIT, total ischemia time; UW,
University of Wisconsin solution
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Introduction
Ischemia–reperfusion injury associated with cold preserva-
tion is well known to influence transplant outcomes (1). The
avoidance of this injury can ensure improvement of
posttransplant graft function and survival (2). Two different
ways have been explored to diminish the injury related to
ischemia–reperfusion: static cold preservation with optimal
solutions, and dynamic preservation devices using different
temperatures ranging from4 to 378C (3).Machine perfusion
has proven its efficacy and is routinely applied for kidney
preservation (4), but is not routinely used for clinical liver
preservation (5). Given the complexity of preserving hepatic
function, most innovative investigations remain in the
experimental domain (6–9).
Recent improvements in hepatic preservation have been
focused on the development of static cold preservation
solutions with different compositions (2,3), owing to the
technical simplicity and clinical feasibility of thismethod. The
modifications in the components, introduced sequentially
American Journal of Transplantation 2015; 15: 395–406
Wiley Periodicals Inc.
C Copyright 2015 The American Society of Transplantation
and the American Society of Transplant Surgeons
doi: 10.1111/ajt.13060
395
in the last 40 years, are based on the change of ionic
composition and on the molecules aiming to reduce
intracellular and interstitial edema, namely osmotic and
oncotic agents (3). Preservation solutions can be classified
according to potassium levels, type of oncotic agents,
presence of antioxidants and of agents protecting from
ischemia–reperfusion damage. Differences in the composi-
tion of the mostly used solutions are shown in Table 1.
Despite the scientific rationale directing the different
compositions, their clinical relevance on liver transplant
outcomes are often questioned due to a lack of properly
powered, prospective randomized designed trials (5).
Recently a systematic review with meta-analysis on 16
randomized clinical trials come to the conclusions that there
was no good evidence of any difference in outcomes when
comparing histidine-tryptophan-ketoglutarate solution
(HTK) with either of the University of Wisconsin solution
(UW) or Celsior solution (CE), but the authors recognized
that the data were limited (10). In this context, the purpose
of this study was to ascertain graft survival in a large
European cohort of patients in relation to liver preservation
with the four most frequently used preservation solutions:
UW, Institute Georges Lopez solution (IGL-1), CE and HTK.
Methods
Study population
Between 1968 and 2012, 118 001 adult liver transplantations (LTs) were
consecutively performed by European centers and collected through the
European Liver Transplant Registry (ELTR). Out of them 106701 were first
LTs and since 2003, there were 43 424 first LTs, of which 42 869 used UW,
CE, HTK or IGL-1 for graft preservation. The ELTR questionnaire is
intentionally limited to the main variables concerning donor and recipient
data, intraoperative details as well as graft and patient outcome updated
every 6 months. The quality of data is routinely controlled by randomly
designated audit visits of contributing centers (5–10 audits per year), which
have confirmed that data from the ELTR are a reliable and credible
representation of LT practice in Europe (11).
Study design
Recipients were divided into four groups in relation to the graft preservation
solution: UW (N¼24 562—57.3%), HTK (N¼ 8696—20.3%), CE
(N¼ 7756—18.1%) and IGL-1 (N¼ 1855—4.3%). The evolution in the use
of the four preservation solutions was assessed. The preservation solution
fluids were chosen at the discretion of the procurement team and the ELTR
questionnaire was blinded to the reason of the choice made by the teams.
The end point of analysis was graft survival in the total study population.
In addition, graft survival was assessed for each group in relation to the
length of total ischemia time (TIT; < or >12 h), to the type of graft since
deceased partial liver grafts (split or reduced) may be more likely to suffer
from ischemia–reperfusion injury, or to the type of indication for LT.
Statistical method
Graft survival was analyzed for all liver grafts comparing UW, CE, HTK and
IGL-1 preservation groups. Analyzed recipient variables were: gender, age,
blood group, BMI, hepatitis B surface antigen (HBsAg), anti-hepatitis C virus
(anti-HCV), creatinine, bilirubin, international normalized ratio (INR), Model
for End-Stage Liver Disease (MELD) score, HIV serology, dialysis, United
Network for Organ Sharing (UNOS) status and main diseases. Donor/graft
variables were: gender, age, blood group, preservation solution and TIT
(number of minutes between portal clamping in the donor and portal
revascularization on the recipient). Transplantation variables were: urgency,
heterotopic/orthotopic, auxiliary LT, bypass, living, domino or deceased
partial grafts including reduced and splits, associated transplantation,
number of LTs per center. Follow-up variables were: date of outcome,
cause of graft loss, cause of death.
Missing data were excluded from the analysis without any imputation.
Categorical and continuous study variables were compared using the
chi-square test and the independent-samples t-test, respectively. To evaluate
if preservation solutions have an impact on graft survival in separate different
transplant subgroups with known different patient survivals (12), sub-groups
analyseswere performed for hepatocellular carcinoma (HCC) and partial grafts
(split or reduced) as well as for the total cohort excluding living related LT.
Survival probabilities were estimated using the actuarial method and were
compared using the log-rank test. The cutoff values for continuous variables
(such as LT center volume, recipient and donor age, ischemia time) were
chosen by plotting the mortality risk ratios at each value, or at pertinent
interval values, for each variable. The value corresponding to the most
relevant change in the risk-ratio was used for the subsequent multivariate
analysis. Multivariate analysis was performed using a Cox proportional
hazards model to identify independent prognostic factors of survival in all
patients. For multivariate analysis, factors with a p 0.15 at univariate
analyses were included. The analysis was adjusted to the center and a
stratifiedCoxmodel analysiswas performed to avoid any confounding effect
of the center. A p 0.05 in the Cox model was considered statistically
significant. All statistical analyses were performed using SAS, Version 9.1,
software (SAS Institute Inc, Cary, NC).
Table 1: Composition of the different cold preservation solutions
compared in the study
CE HTK IGL-1 UW
mOsm/L 320 310 290 320
HES – – – 0.25
PEG-35 – – 0.03 –
Naþ 100 15 120 27
Kþ 15 10 25 125
Cl – 50 – –
Mg2þ 13 4 – 5
Ca2þ 0.25 0.015 0.5
HCO3
 – – 5
SO4
 – – 5 4
PO4 – – 25 25
H2PO4 – – – –
Histidine 30 198 – –
Mannitol 60 30 – –
Lactobionate 80 – 100 105
Raffinose – – 30 30
Glutathione 3 – 3 3
Adenosine – – 5 5
Glutamate 20 – – –
Concentrations are expressed in mmol/L, except otherwise
specified.
HES, hydroxyethyl starch; PEG-35, polyethylene glycol 35 kDa.
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Results
Use of preservation solutions in Europe
Since 1983, when data collection started routinely in the
ELTR, the unique solution used in Europe for static liver
preservation was Collins solution. A maximum of 450
transplants per year were performed, with its use peaking
in 1987. UW was introduced in 1987 and peaked in use in
2001 at 3750 transplants/year. Alternative solutions to UW
emerged in the 1990s: HTK started to be used by 1991, CE
by 1998, and IGL-1 by 2003. During the study period
between 2003 and 2012, UW use decreased while the use
of alternative solutions increased progressively (Figure 1).
The final percentages of solutions used in 2012 were: 36%
for UW, 29% for HTK, 23% for CE, 10% for IGL-1 and 2%
for others.
Preservation solution versus graft survival—all
transplants
Considering the whole cohort of preserved liver grafts
within the study period, some differences between study
groups were found related to recipient and donor data or to
transplant procedure.
As shown in Table 2, HTK andUWpresented higher rates of
female recipients (p< 0.0001), IGL-1 had older recipient
age (p< 0.0001) with the higher MELD score (p< 0.0001)
and the higher proportion of patient having dialysis
(p<0.0001), CE had older donor age (p<0.0001) and
more patients with cancer but less with fulminant hepatitis,
IGL-1 and UW had longer TITs and higher proportion of
partial grafts (split or reduced), but HTK presented higher
rate of living donor LT. The BMI was identical in all groups.
Graft survival between the different solutions was found to
be significantly different (Global Log Rank p< 0.0001).
Overall UW, IGL-1 and CE were associated with better
survival, compared to HTK (1 year: 83%, 82%, 82% vs.
77%; 5 years: 69%, 68%, 68% vs. 64%, respectively, for
UW, IGL-1, CE and HTK) (Figure 2A). Further analysis
demonstrated that HTK also provided significantly lower
survival than the other solutions when excluding living
transplantations (Figure 2B).
In addition to the preservation solutions, all variables known
to affect graft survival were also submitted to univariate
analysis. Prolonged TIT, patients with HCC and transplan-
tation with a partial liver graft were found to be associated
with lower graft survival (Figure 3). Given that these
variables were unequally distributed in the different
preservation solution groups, graft survival was concretely
evaluated by comparing all the solutions in the context of
each of these factors, in subgroup studies (Table 3).
Preservation solution versus graft survival in relation
to TITs
As shown in Figure 3A, a significant effect of the type of
preservation solution was observed on graft survival for
TITs shorter than 6 h (Global LogRank p<0.0001) (at 1 year:
86%, 84% vs. 82%, 82%; at 5 years: 73%, 76% vs. 67%,
71%, respectively, for UW, IGL-1, CE and HTK). The effect
was more evident within 6 and 12 h of TIT (Global Log Rank
p< 0.0001), UW providing higher survival than the others
while HTK showed the lowest survival (at 1 year: 83%,
82%, 82%, 77%; at 5 years: 70%, 67%, 68%, 63%,
respectively, for UW, IGL-1, CE and HTK) (Figure 3B). This
was confirmed for longer TIT (between 12 and 18 h), HTK
providing lower survival than the other solutions (Global Log
Rank p< 0.0001) (at 1 year: 78%, 84%, 80%, 69%; at 5
years: 65%, 69%, 66%, 52%, respectively, for UW, IGL-1,
CE and HTK) (Figure 3C). No significant differences were
observed with TIT greater than 18h but the number of
Figure 1: Use of preservation solutions in liver transplantation in Europe from 2003 to 2012. Absolute numbers.
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patients was limited: UW (n¼ 60), IGL-1 (n¼ 3), CE (n¼ 11)
and HTK (n¼ 30) (data not shown).
Preservation solution versus graft survival in HCC
patients
All transplanted patients with HCC were selected and
analyzed as a subgroup, since the incidence of HCC was
different between preservation solution groups (p<0.001).
Overall graft survival was significantly affected by preser-
vation solutions (Global Log Rank p<0.0001) (Figure 4).
HTK showed the worst survival over time when compared
to the three other ones (HTK vs. CE, HTK vs. UW, and HTK
vs. IGL-1, all p¼ 0.0001). IGL-1, UW, CE and HTK graft
survivals were 84%, 87%, 85%, 76%, respectively, at
1 year and 63%, 67%, 66%, 50%, respectively, at 5 years.
Preservation solution versus graft survival in patients
transplanted with partial deceased grafts
In patients receiving partial grafts, a significant difference in
graft survival between preservation solutions was also
demonstrated (at 1 year: 72%, 89%, 76%, 69%; at 5 years:
62%, 80%, 66%, 54%, respectively, for UW, IGL-1, CE and
HTK) (Global Log Rank p¼ 0.009). As indicated in Figure 5,
HTK was related to the worse survival when compared to
the other solutions. IGL-1 provided a significantly better
graft survival compared to HTK (p¼ 0.0007) and UW
(p¼0.001).
Multivariate analysis of graft survival
After adjusting for centers, HTK preservation was indepen-
dently associated with a 10% increased risk of graft loss on
multivariate analysis when comparedwith CE, UW or IGL-1
(RR¼1.10; p¼ 0.02) (Table 4). The other factors influencing
graft survival were by decreasing order of importance:
recipient HIV positivity (RR¼ 1.50), donor age 65 years
(RR¼1.41), recipient HCV positivity (RR¼ 1.40), main
disease: acute hepatic failure (RR¼1.34), use of a partial
liver graft (RR¼ 1.30), recipient age 60 years (RR¼ 1.29),
no identical ABO compatibility (RR¼ 1.24), recipient HBsAg
negativity (RR¼1.24), TIT 12h (RR¼1.19), male recipi-
ent (RR¼ 1.10) and main disease other than cirrhosis
(RR¼1.09).
Cause of death or graft loss in relation to
preservation solutions
Considering hepatic complications, the proportion of graft
loss related to primary nonfunction or dysfunction (13.7%)
and to biliary complications (6%) were the highest in the
HTK group, as well as graft loss related to infectious
complications (19.8%) (Table 5). Vascular complications
(9.1%) and rejection (4.7%) were the highest with UW, and
Table 2: Demographics of patients undergoing liver transplantation
Preservation solution N CE 7756 HTK 8696 IGL-1 1855 UW 24562 p
Recipent characteristics
Age (year) (meanSD) 5310 5211 5410 5211 <0.0001
Female (%) 27% 34% 27% 33% <0.0001
BMI (kg/m2) (meanSD) 25.66.8 266.3 26.618.5 26.222.4 0.21
Disease
Cirrhosis 54% 60% 60% 61% <0.0001
Cancer 31% 18% 23% 17% <0.0001
FUHE 4% 6% 6% 7% <0.0001
Others 10% 15% 12% 15% <0.0001
MELD score (meanSD) 17.18.9 189.2 1910.2 17.58.7 <0.0001
INR (meanSD) 1.81.3 1.71 21.6 1.71.5 <0.0001
Bilirubin (mg/dL) (meanSD) 5.58.4 6.69.5 6.69.5 6.29 <0.0001
Creatinine (mg/dL) (meanSD) 1.10.8 1.21 1.21 1.20.9 <0.0001
Dialysis 4.9% 6.9% 7.0% 2.4% <0.0001
UNOS status (%)
ICU-bound 7% 8% 14% 9% <0.0001
Continuous medical care 16% 21% 13% 14% –
Continuous hospitalization 56% 45% 50% 48% –
At home with normal function 21% 26% 22% 30% –
Transplant characteristics
Total ischemia time (min) (meanSD) 457162 464226 477164 500180 <0.0001
Urgency (%) 6% 11% 9% 9% <0.0001
Partial liver (split or reduced) (%) 2.8% 2.2% 5% 4.5% <0.001
Donor characteristics
Age (year) (meanSD) 5418 4817 5118 4817 <0.0001
Female (%) 43% 44% 43% 43% 0.22
Living related 1.5% 21.1% 2.3% 2.6% <0.0001
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Figure 2: (A) Graft survival after liver transplantation according to preservation solution in all patients. (B) Graft survival after liver
transplantation according to preservation solution excluding living transplantation.
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Figure 3: Graft survival after liver transplantation according to preservation solution in different subgroups of grafts with
different total ischemia time.
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those related to hemorrhage (3.1%) were the highest
with IGL-1.
Discussion
By analyzing a large cohort of first LTs performed in a 10-
year period, this retrospective study shows that UW
considered for long the gold standard preservation solution,
has been less frequently used in Europe in the recent years
and currently alternative solutions are used in 64% of LT.
This study shows that compared to UW, graft survival is at
least equally preserved with the use of IGL-1, slightly
decreased with CE but significantly reduced with HTK
compared to the three other solutions. In subgroups of
transplanted patients with factors known to adversely
affect the graft survival, the data confirm that HTK provides
significantly lower survival than CE, IGL-1 and UW for HCC
patients, for TIT exceeding 6 h, for partial deceased grafts
and for the total population excluding living related trans-
plantations, more widely used with HTK. Multivariate
analysis confirmed HTK as an independent risk factor
increasing the probability of graft loss by 10%. Other
classical independent factors were also identified in this
analysis. The difference in graft survival was mainly
observed within the early posttransplant period and was
thereafter stable on the long term, except for HCC and
partial grafts for which the difference enlarged beyond the
first and second year of follow up.
While initial studies comparing HTK and UWwere unable to
demonstrate any statistical difference in liver graft survival,
possibly because of the limited number of patients, more
recently a study made on a large sample size based on
UNOS data and comparing HTKwith UW, identified HTK as
an independent risk factor of graft loss. This was observed
especiallywith donation after cardiac death (DCD) allografts
and thosewith cold ischemia time over 8 h (13). The authors
found indeed a disproportionate use of HTK in DCD
recoveries in recent years likely because it was thought
that the lower viscosity of HTK would be particularly
beneficial during aDCD procurement. Overall, these results
were observed even considering that HTK livers had shorter
cold ischemia time and their recipients showed better
characteristics in relation to the rate of pretransplant
hospitalization, life support prior to liver transplant.
The present study based on the ELTR, and powered with a
significant sample size allowing reliable multivariate analy-
sis is in agreement with these results. At the difference of
the UNOS study, the proportion of DCD donors since 2008
in Europe was only 2.8% (2.4% for HTK vs. 2.9% for the
other solutions [NS]), suggesting that HTK effect was
independent of this factor. Noteworthy, the deleterious
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Figure 3: (Continued)
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effect of HTK was observed independently of the duration
of ischemia time: both studies evidenced that for ischemia
time exceeding 6 h HTK preservation experienced the
lowest graft survival when compared to the other
solutions. Also, in one of the largest single-center study
reported by Mangus et al (14), a trend toward reduced
survival was observed for HTK preserved livers suffering
from more than 12 h of cold ischemia time. In the
evaluation of subgroups focused on HCC and on partial
grafts, factors well known to be associated to reduced
survival, the risk of using HTK preservation solution was
confirmed.
These limitations of HTK were also reported by Nardo et
al (15) when compared to CE, suggesting a lower survival
with the use of HTK. Our study is in line with these results
and lower graft survivals were achieved with HTK
compared to CE in the global analysis of all transplants, in
HCC recipients and also in partial grafts.
Concerning the comparison between HTK and IGL-1, to our
knowledge therewas no published data and our study is the
first one to report significantly better results for IGL-1.
Regarding IGL-1 and UW, Donde´ro et al (16) reported
equivalent clinical results in a prospective randomized study
including 140 patients from a single-center trial. This
equivalence was confirmed in the current study with
regard to graft survival since IGL-1 shows similar graft
survival than UW in the global cohort as well as in the sub-
group analyses. Graft survival with IGL-1 exceeds however
UW in case of LT with partial grafts.
Table 3: Univariate analysis of graft survival
Variable Option N 1 year 3 years 5 years 8 years 10 years p
Recipient age 15–45 years 9634 83% 76% 71% 66% 63% <0.0001
45–60 years 22106 82% 74% 69% 62% 55%
60 years 11052 79% 70% 64% 56% 49%
Recipient HBsAg Negative 34441 81% 73% 68% 61% 54% <0.0001
Positive 5099 85% 79% 75% 70% 68%
Recipient anti-HCV Negative 28179 83% 76% 71% 65% 59% <0.0001
Positive 11161 81% 69% 62% 54% 46%
Recipient HIV Negative 31183 82% 74% 68% 61% 53% <0.0001
Positive 588 77% 64% 59% 47% –
Urgency No 33659 82% 74% 68% 62% 56% <0.0001
Yes 3238 72% 66% 62% 59% 59%
UNOS status 1 3307 69% 64% 61% 58% 57% <0.0001
2 5788 76% 69% 64% 56% 52%
3 18436 83% 75% 69% 63% 55%
4 10242 85% 78% 72% 65% 59%
Preservation Celsior 7749 82% 73% 68% 59% 54% <0.0001
Solution HTK 8657 77% 69% 64% 57% 56%
IGL 1855 82% 75% 68% 66% –
UW 24531 83% 75% 69% 63% 56%
Ischemia time [1–6 h] 9781 84% 76% 71% 65% 64% <0.0001
[6–12 h] 26227 82% 74% 68% 61% 54%
[12–18h] 4065 76% 70% 63% 56% 48%
[18–36h] 104 78% 68% 66% 66% 66%
Type of graft Cad. Full size 37428 82% 74% 69% 62% 55% <0.0001
Domino 473 81% 70% 66% 45% 42%
Living 2547 79% 72% 66% 61% 59%
Reduced 97 68% 62% 52% 52% –
Split 1483 74% 68% 64% 56% 54%
Main disease AHF 2653 72% 67% 64% 60% 60% <0.0001
Cancer 8555 83% 70% 62% 54% 46%
Cirrhosis 25333 82% 75% 69% 63% 57%
Others 5829 82% 76% 72% 65% 59%
LT1 donor age 65 years Yes 8045 80% 69% 62% 54% 47% <0.0001
No 30808 82% 75% 70% 63% 57%
ABO blood group Compatible 2435 77% 70% 66% 62% 58% <0.0001
Identical 39170 82% 74% 68% 62% 55%
No identical 259 69% 62% 59% 50% –
No LT center <500 No 34655 82% 74% 68% 61% 56% 0.008
Yes 8137 80% 72% 67% 62% 52%

(1) ICU-bound, (2) Continuous hospitalization, (3) Continuous medical care, (4) At home with normal function.
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Figure 5: Graft survival after liver transplantation according to preservation solution. Sub-group of patients receiving grafts (split or
reduced).
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Figure 4: Graft survival after liver transplantation according to preservation solution. Sub-group of HCC patients.
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The mechanisms by which HTK leads to a worst overall
preservation of the liver are not fully understood. We could
hypothesize that it could be related to viscosity, to the
oncotic value of the solution or to the presence of
antioxidant agents (3). In principle lower viscosity favors
an efficient organwashout and the diffusion of preservation
solution to the distal organ tissue, limiting biliary compli-
cations well described to occur after transplantation (17).
The benefit of a lower viscosity has been documented in an
experimentalmodel of LT in rats inwhich an initial flushwith
HTK before UW preservation (being UWmore viscous than
HTK) improved enzyme release and bile production after
transplantation (18). However, the efficiency of the solution
is also strongly dependent on the presence of antioxidants
and protective agents. HTK composition is poor in these
agents when compared to the other solutions. Another
factor such as the oncotic agent plays a key role in
preventing tissue edema, andHTK does not contain it when
compared to IGL-1 polyethylene glycol 35 kDa [PEG-35] and
UW hydroxyethyl starch [HES] (19). Limitation of interstitial
edema becomes crucial in the cold preservation of organs,
especially liver and pancreas where this edema is determi-
nant for limiting organ function after reperfusion (20).
Furthermore, in steatotic livers themicrocirculation through
the sinusoids is reduced as a consequence of the fat
accumulated in hepatocytes that increase their volume
collapsing the sinusoidal vascular space. In this situation an
important edema would even worsen and reduce the
vascular space impeding the perfusion of the organ. Thus,
reduction of edema in steatotic livers with HES or PEG-35
should improve themicrocirculation and the preservation of
the organ through the efficient flushing with the preserva-
tion solution (21). These benefits of the oncotic agent have
been extensively described on fatty livers experimentally (2)
and should be balanced by the compromise of providing an
acceptable low viscosity to the solution. In our study, since
the steatosis item was not available in the ELTR question-
naire before 2008, this variable could not be evaluated.
The superior benefits of CE versus HTK could be related to
the different composition and presence of protective
agents, in favor of CE, provided that neither contain oncotic
agents. This is supported by in vitro studies demonstrating
the superior protection conferred by CE as previously
reported by several authors. In this sense, CE induced a
superior protection against preservation injury of human
liver endothelial cells in culture in terms of LDH and
maintenance of energy metabolism after reperfusion (22).
This is also consistent with the report by Straatsburg et
al (23) showing in an isolated rat liver model that rat livers
Table 5: Cause of death or graft loss
Preservation solution CE (%) HTK (%) IGL (%) UW (%)
pN 7756 8696 1855 24562
Infection 12.9 19.8 16.9 13.3 <0.0001
Vascular 8.7 5.9 4.9 9.1 <0.0001
Nontumoral reccurence 13.8 4.6 9.8 11.8 <0.0001
Intaoperative death 2.1 1.7 0.6 1.8 NS
Tumoral reccurence 8.1 10.5 3.7 9.6 0.0004
Others 6.8 6.5 8.3 7.2 NS
PNF or dysfunction 8.3 13.7 7.7 7.1 <0.0001
Cardiovascular 5.6 7.1 7.9 5.8 NS
Tumor de novo 4.5 3.0 5.5 7.6 <0.0001
Rejection 4.0 2.3 3.4 4.7 0.0001
Biliary 2.8 6.0 3.1 4.2 <0.0001
Pulmonary 4.9 3.5 4.0 3.9 NS
Other hepatic 3.4 5.3 3.7 3.5 0.005
Cerebrovascular 4.2 2.8 3.7 2.8 0.04
GI 2.7 2.8 1.5 2.2 NS
Renal 0.7 1.2 1.0 1.0 NS
Hemorrhage 0.8 0.9 3.1 0.5 <0.0001
Hepatic infarction 1.3 0.0 0.6 0.2 <0.0001
Table 4: Multivariate analysis of risk factors for graft loss in the
global cohort. Center stratified Cox regression analysis
Risk factors p RR CI 95%
1. Recipient HIV (þ) <0.0001 1.50 [1.29; 1.75]
2. Donor age 65 years <0.0001 1.41 [1.32; 1.51]
3. Recipient anti HCV (þ) <0.0001 1.40 [1.34; 1.47]
4. Main disease: ACHF <0.0001 1.34 [1.22; 1.47]
5. Partial liver graft <0.0001 1.30 [1.16; 1.44]
6. Recipient age 60 years <0.0001 1.29 [1.23; 1.37]
7. Non-ABO isogroup <0.0001 1.24 [1.14; 1.34]
8. Recipient HBsAg () <0.0001 1.24 [1.15; 1.33]
9. Ischemia time 12h <0.0001 1.19 [1.11; 1.27]
10. Recipient male <0.0001 1.10 [1.05; 1.15]
11. HTK 0.02 1.10 [1.01; 1.20]
12. Main disease: not cirrhosis 0.01 1.09 [1.04; 1.15]
RR, risk ratio; CI, confidence interval; ACHF, acute hepatic failure.
Cox model with 34520 observations.
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were better preserved in CE than HTK with increased bile
secretion and reduced cell death. Also in amodel of isolated
porcine hepatocyte preservation, CE induced less necrosis
and DNA fragmentation than HTK (24).
Interestingly, in partial grafts, IGL-1 provided better survival
than the other solutions. This could be explained by recent
experimental studies showing the relation between this
solution and the increase of mediators promoting liver
regeneration such as AMP-activated protein kinase, mech-
anisms not induced by UW (25). This fact should be
considered given the potential benefits of activation of
regeneration mechanisms in partial graft LT.
This study has some limitations. It is retrospective and
nonexhaustive of all the data concerning particularly the
early posttransplant course. The different groups presented
some differences concerning donors, recipients, indica-
tions or details of the operative procedure. However, the
largemulticentric cohort of patients prospectively collected
through the ELTR, allowed a multivariate as well as
different subgroup analyses, converging in a robust
evaluation of the influence of preservation solutions on
graft outcome. Also, owing to the 10-year period of the
study, a ‘‘time effect’’ could be suspected to impact
the graft survival, with a wider use of new solutions in the
recent period. This was not the case since a very small
difference in graft survival was observed between the
period 2003–2007 and that of 2008–2012 (1-year graft
survival 82% vs. 81%, respectively) paradoxically in favor of
the oldest period. Therefore the time period has not
affected the independent effect of HTK. Finally any center
effect on graft outcome was excluded by the stratification
of the Cox regression model.
In conclusion, the experience here reported from the ELTR
clearly shows that preservation with HTK is an independent
factor of graft loss after transplantation. Detailed analysis of
the data suggests that UW and IGL-1 provide the best graft
survival with CE results being close. The differential effects
of the solutions are attributable to their different compo-
sitions raising the importance of each component on the
preservation capacity of the solutions available. These
results may serve as a basis to design future prospective
randomized clinical trials.
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